ArticleRapid communications in mass spectrometry : RCM2026
Profiling and Identification of Novel Tiletamine Metabolites in Human Urine and Hair by Liquid Chromatography Coupled With Quadrupole-Orbitrap Mass Spectrometry.
Article in Rapid communications in mass spectrometry : RCM, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleTiletamine, an animal tranquilizer increasingly misused by humans, lacks comprehensive metabolic characterization in authentic biological matrices. To date, tiletamine phase II metabolism remains poorly characterized. This study investigated the metabolic fate of tiletamine in human urine and hair by identifying novel metabolites and elucidating biotransformation pathways relevant to forensic toxicological monitoring.
methodsAuthentic human urine (n = 3) and hair (n = 2) samples from individuals with documented tiletamine exposure were analyzed using liquid chromatography coupled with Q Extractive HF hybrid quadrupole-Orbitrap high-resolution mass spectrometry (LC-QE-HF-MS). Metabolites were detected and identified based on full-scan MS and data-dependent MS/MS (ddMS
resultsA total of 14 urinary metabolites were identified, 11 of which (4 phase I and 7 phase II) were previously unreported. Hydroxylation was the predominant phase I process, whereas glucuronidation predominated among phase II reactions. Methylation and glucuronidation were identified as previously unreported metabolic pathways. In hair samples, tiletamine and four metabolites, including three reduced metabolites and T1, were identified for the first time. In addition, three metabolic transformations, namely, reduction, hydroxylation, and methylation, were newly identified in this matrix. Notably, T1 exhibited substantially higher signal intensities than all other metabolites across all urine samples.
conclusionsThis study substantially expands the known urinary metabolome by identifying novel phase I and II metabolites. The consistently high abundance of T1 in urine suggests that it is a promising urinary biomarker for monitoring tiletamine use. These findings broaden the range of analytical targets available for toxicological screening and confirmational analysis, thereby improving the detection and monitoring of tiletamine exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.